A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study.
Fiche publication
Date publication
février 2023
Journal
Revue neurologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Gauer L, Bigaut K, Berger É, Debouverie M, Moreau T, de Sèze J
Lien Pubmed
Résumé
Ten years after its authorization, data about fingolimod use in real-world setting is still scarce. Here we describe the long-term evolution of fingolimod-treated relapsing-remitting MS (RRMS) patients and determine baseline characteristics associated with risk of relapses or disability.
Mots clés
Fingolimod, Follow-up studies, France, Multiple sclerosis, Relapsing remitting, Risk factors, Treatment outcome
Référence
Rev Neurol (Paris). 2023 02 23;: